Alnylam Pharma (ALNY) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. DOX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. SPY

Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 8c

Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity

November 5, 2020 8:00 AM EST

Achieved Third Quarter 2020 ONPATTRO® Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Product Worldwide

Achieved Third Quarter 2020 GIVLAARI® Global Net Product Revenue of $16.7 Million, with More Than 150 Patients on Commercial Product Worldwide

Received Positive Opinions for OXLUMO (lumasiran) and LEQVIO® (inclisiran) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), Positioning the Company for Potentially Four Approved RNAi Therapeutic Medicines by Year-End 2020

Increased 2020 Guidance Range for ONPATTRO Revenue from $280-$300 Million... More